March 29, 2021 – Philadelphia, PA – We are pleased to announce that Ms. Michie Ong will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Senior Director of Global Quality and Compliance.

In this role, Ms. Michie Ong will be responsible for setting the global quality standards and integrating the quality systems for all WuXi ATU sites. She will be working closely with quality leaders in US, UK and China to continuously improve our quality systems and processes in order to support the rapid growth of the business. She will also be leading the Philadelphia Pre-Licensure Inspection activities and setting up the quality professional training.

Michie has over 14 years of pharmaceutical experience. Prior to joining WuXi ATU, she has held various technical and managerial positions in quality, compliance, and external relations throughout her career, spanning from site operations to global functions. She worked and lived in US, China, Japan and Singapore, and played significant roles in biologics facility start-up, technical transfers, pre-approval inspections for product launches, quality management system implementation and quality oversight in operations. Her work experience included manufacturing quality assurance, quality systems, compliance operations, quality improvement initiatives, deviation and investigation, risk management, CAPA and change control.

Prior to the industry experience, Michie worked at National University of Singapore for 3 years. Her major accomplishments included setting up a new toxicology laboratory, securing program funding and publishing technical research papers.

Michie graduated from Monash University, Australia with a Bachelor of Science degree in Biotechnology.

We are excited to welcome Michie to WuXi Advanced Therapies!


About WuXi Advanced Therapies (ATU)

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit


Media Contact:

Min Park
Global Head of Marketing
WuXi Advanced Therapies